Work

134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)

Year: 2018

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(18)30409-x

Authors: M. Reck, M.A. Socinski, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodríguez-Abreu, D. Moro-Sibilot, C.A. Thomas, F. Barlesi

Institutions: German Center for Lung Research, LungenClinic Grosshansdorf, Florida Hospital Cancer Institute, AdventHealth, Azienda Unità Sanitaria Locale Della Romagna, Instituto Nacional del Tórax, Moscow City Oncology Hospital №62, Shikoku Cancer Center, Hospital Universitario Insular de Gran Canaria, Centre Hospitalier Universitaire de Grenoble, New England Cancer Specialists, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2796527855

FWCI: 0.851

Cites:

Cited by: 10

Related to: 10